Prostate cancer can be detected by genetic testing to obtain the corresponding information. The commonly used genetic tests in clinical practice include: 1) the susceptibility gene of prostate cancer, also known as BRCA gene; 2) the FGFR fibroblast growth factor receptor associated with prostate cancer angiogenesis; 3) the vascular endothelial growth factor VEGF and the receptor VEGFR; 4) the platelet-derived growth factors, such as PDGF and Currently, prostate cancer patients are mainly tested for BRCA gene carriage or mutation, and PARP-1 inhibitors can be selected according to the expression and mutation of BRCA gene. The treatment of advanced prostate cancer with metastasis, especially with ARP-1 inhibitors, can provide better results and improve the quality of life of patients.